Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma

M. F. Roesdi, T. J. Postma, O. S. Hoekstra, C. J. Van Groeningen, J. G. Wolbers, J. J. Heimans

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Scopus)


Combination chemotherapy with procarbazine, CCNU and vincristine (PCV) may be effective in patients with recurrent glioma. Response monitoring is mandatory, but radiological response evaluation is often difficult. We evaluated Thallium-201 (201Tl) SPECT as a response parameter in ten patients treated with intensive PCV chemotherapy for recurrent glioma. 201Tl-SPECT studies showed early changes (decreasing volume and intensity) in nine patients and these changes were more pronounced than radiological findings. 201Tl-SPECT results after completion of chemotherapy seemed to correlate with clininal findings during follow up. We conclude that 201Tl-SPECT may contribute to the assessment of response in patients treated with PCV chemotherapy for recurrent glioma.

Original languageEnglish
Pages (from-to)251-255
Number of pages5
JournalJournal of Neuro-Oncology
Issue number3
Publication statusPublished - 1998


  • Chemotherapy
  • Recurrent glioma
  • Response parameter
  • Thallium-201 SPECT

Cite this